Merck Manual

Please confirm that you are a health care professional

Loading

Fabry Disease

(Fabry's Disease; Angiokeratoma Corporis Diffusum)

By

Matt Demczko

, MD, Sidney Kimmel Medical College of Thomas Jefferson University

Last full review/revision Apr 2020| Content last modified Apr 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Fabry disease is a sphingolipidosis, an inherited disorder of metabolism, caused by deficiency of alpha-galactosidase A, which causes angiokeratomas, acroparesthesias, corneal opacities, recurrent febrile episodes, and renal or heart failure.

For more information, see table Some Sphingolipidoses.

Fabry disease is an X-linked deficiency of the lysosomal enzyme alpha-galactosidase A, which is needed for normal trihexosylceramide catabolism. Glycolipid (globotriaosylceramide) accumulates in many tissues (eg, vascular endothelium, lymph vessels, heart, kidney).

Diagnosis in males is clinical, based on appearance of typical skin lesions (angiokeratomas) over the lower trunk and by characteristic features of peripheral neuropathy (causing recurrent burning pain in the extremities), corneal opacities, and recurrent febrile episodes. Death results from renal failure or cardiac or cerebral complications of hypertension or other vascular disease. Heterozygous females are usually asymptomatic but may have an attenuated form of disease often characterized by corneal opacities.

Diagnosis of Fabry disease is by DNA analysis and/or assay of galactosidase activity—prenatally in amniocytes or chorionic villi and postnatally in serum or white blood cells. (Also see testing for suspected inherited disorders of metabolism.)

Treatment of Fabry disease is enzyme replacement with recombinant alpha-galactosidase A (agalsidase beta) combined with supportive measures for fever and pain. Kidney transplantation is effective for treating renal failure.

Drugs Mentioned In This Article

Drug Name Select Trade
FABRAZYME
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Overview of Persistent Truncus Arteriosus
Video
Overview of Persistent Truncus Arteriosus
3D Models
View All
Cystic Fibrosis: Defective Chloride Transport
3D Model
Cystic Fibrosis: Defective Chloride Transport

SOCIAL MEDIA

TOP